Wednesday, April 07, 2021 7:26:42 AM
Transmedics group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Lung INSPIRE Trial, OCS Lung Expand Trial, OCs Heart EXPAND and PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. It is also focused on developing additional OCS products for kidney transplantation.
New York Yankees and Duke Basketball
Recent TMDX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:15:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:15:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 10:47:28 PM
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 05/21/2026 08:05:00 PM
- TransMedics to Present at the William Blair 46th Annual Growth Stock Conference • PR Newswire (US) • 05/19/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/07/2026 08:50:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 08:15:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:05:20 PM
- TransMedics Reports First Quarter 2026 Financial Results • PR Newswire (US) • 05/05/2026 08:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 05:54:29 PM
- TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH • PR Newswire (US) • 04/29/2026 01:26:00 PM
- The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms • PR Newswire (Canada) • 04/29/2026 01:00:00 PM
- The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms • PR Newswire (US) • 04/29/2026 01:00:00 PM
- TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting • PR Newswire (US) • 04/23/2026 11:00:00 AM
- TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026 • PR Newswire (US) • 04/21/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/10/2026 11:50:57 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 11:48:35 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 09:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 11:12:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 11:09:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 02:40:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 01:40:09 AM
